254 related articles for article (PubMed ID: 33041218)
1. Adjuvant Treatment Modalities, Prognostic Factors, and Outcome of the Uterine Carcinosarcoma.
Kahramanoglu I; Demirkiran F; Turan H; Bese T; Cebi S; Ilvan S; Arvas M
J Obstet Gynaecol Can; 2021 Jan; 43(1):34-42. PubMed ID: 33041218
[TBL] [Abstract][Full Text] [Related]
2. Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma.
Matsuo K; Omatsu K; Ross MS; Johnson MS; Yunokawa M; Klobocista MM; Im DD; Bush SH; Ueda Y; Takano T; Blake EA; Hasegawa K; Baba T; Shida M; Satoh S; Yokoyama T; Machida H; Adachi S; Ikeda Y; Iwasaki K; Miyake TM; Yanai S; Nishimura M; Nagano T; Takekuma M; Takeuchi S; Pejovic T; Shahzad MM; Ueland FR; Kelley JL; Roman LD
Gynecol Oncol; 2017 Apr; 145(1):78-87. PubMed ID: 28215838
[TBL] [Abstract][Full Text] [Related]
3. Uterine Carcinosarcomas - Diagnosis and Management.
Denschlag D; Ulrich UA
Oncol Res Treat; 2018; 41(11):675-679. PubMed ID: 30317231
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group.
Harano K; Hirakawa A; Yunokawa M; Nakamura T; Satoh T; Nishikawa T; Aoki D; Ito K; Ito K; Nakanishi T; Susumu N; Takehara K; Watanabe Y; Watari H; Saito T
Int J Clin Oncol; 2016 Feb; 21(1):168-76. PubMed ID: 26084780
[TBL] [Abstract][Full Text] [Related]
5. The Impact of Adjuvant Therapy on Survival and Recurrence Patterns in Women With Early-Stage Uterine Carcinosarcoma: A Multi-institutional Study.
Guttmann DM; Li H; Sevak P; Grover S; Jacobson G; Feldman A; Rubin S; Chu C; Bhatia S; Elshaikh MA; Lin LL
Int J Gynecol Cancer; 2016 Jan; 26(1):141-8. PubMed ID: 26509850
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes of uterine carcinosarcoma: results of 94 patients.
Gokce ZK; Turan T; Karalok A; Tasci T; Ureyen I; Ozkaya E; Kose MF; Tulunay G
Int J Gynecol Cancer; 2015 Feb; 25(2):279-87. PubMed ID: 25611900
[TBL] [Abstract][Full Text] [Related]
7. Uterine Sarcoma: Clinical Presentation, Treatment and Survival Outcomes in Thailand.
Potikul C; Tangjitgamol S; Khunnarong J; Srijaipracharoen S; Thavaramara T; Pataradool K
Asian Pac J Cancer Prev; 2016; 17(4):1759-67. PubMed ID: 27221849
[TBL] [Abstract][Full Text] [Related]
8. Malignant Mixed Müllerian Tumour of the Uterus: Analysis of 44 Cases.
Grasso S; Loizzi V; Minicucci V; Resta L; Camporeale AL; Cicinelli E; Cormio G
Oncology; 2017; 92(4):197-204. PubMed ID: 28092915
[TBL] [Abstract][Full Text] [Related]
9. Stage I uterine carcinosarcoma: Matched cohort analyses for lymphadenectomy, chemotherapy, and brachytherapy.
Seagle BL; Kanis M; Kocherginsky M; Strauss JB; Shahabi S
Gynecol Oncol; 2017 Apr; 145(1):71-77. PubMed ID: 28317560
[TBL] [Abstract][Full Text] [Related]
10. Review of Recommended Treatment of Uterine Carcinosarcoma.
Menczer J
Curr Treat Options Oncol; 2015 Nov; 16(11):53. PubMed ID: 26374341
[TBL] [Abstract][Full Text] [Related]
11. [Clinical analysis of 12 cases of uterine carcinosarcoma].
Wang LH; Xiong Y; Li YF; Li JD; Feng YL; Li YJ; Chen C; Chen L
Ai Zheng; 2008 May; 27(5):516-9. PubMed ID: 18479602
[TBL] [Abstract][Full Text] [Related]
12. Uterine sarcoma: clinicopathological characteristics, treatment and outcome in Iran.
Ghaemmaghami F; Karimi-Zarchi M; Gilani MM; Mousavi A; Behtash N; Ghasemi M
Asian Pac J Cancer Prev; 2008; 9(3):421-6. PubMed ID: 18990014
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors and treatment outcomes of patients with uterine sarcoma: analysis of 127 patients at a single institution, 1989-2007.
Park JY; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
J Cancer Res Clin Oncol; 2008 Dec; 134(12):1277-87. PubMed ID: 18506484
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant therapy and prognosis in uterine carcinosarcoma.
Chiang CY; Huang HJ; Chang WY; Yang LY; Wu RC; Wang CC; Tung HJ; Chao A; Lai CH
J Formos Med Assoc; 2021 Nov; 120(11):1977-1987. PubMed ID: 33992491
[TBL] [Abstract][Full Text] [Related]
15. Multimodality adjuvant therapy and survival outcomes in stage I-IV uterine carcinosarcoma.
McEachron J; Heyman T; Shanahan L; Tran V; Friedman M; Gorelick C; Economos K; Singhal PK; Lee YC; Kanis MJ
Int J Gynecol Cancer; 2020 Jul; 30(7):1012-1017. PubMed ID: 32447295
[TBL] [Abstract][Full Text] [Related]
16. Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival.
Krivak TC; Seidman JD; McBroom JW; MacKoul PJ; Aye LM; Rose GS
Gynecol Oncol; 2001 Oct; 83(1):89-94. PubMed ID: 11585418
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of chemotherapy and radiotherapy in the adjuvant management of uterine carcinosarcoma: a population-based analysis.
Ding L; Bi Z; Wu J; Zhu J; Yu Y; Yao HR; Liu YM
Arch Gynecol Obstet; 2023 Mar; 307(3):891-901. PubMed ID: 35708782
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological characteristics, treatment and outcomes in uterine carcinosarcoma and grade 3 endometrial cancer patients: a comparative study.
Zhu J; Wen H; Bi R; Wu X
J Gynecol Oncol; 2016 Mar; 27(2):e18. PubMed ID: 26463439
[TBL] [Abstract][Full Text] [Related]
19. Tumor characteristics and outcome of uterine carcinosarcoma in women aged ≥80 years.
Matsuo K; Ross MS; Yunokawa M; Johnson MS; Machida H; Omatsu K; Klobocista MM; Im DD; Satoh S; Baba T; Ikeda Y; Bush SH; Hasegawa K; Blake EA; Takekuma M; Shida M; Nishimura M; Adachi S; Pejovic T; Takeuchi S; Yokoyama T; Ueda Y; Iwasaki K; Miyake TM; Yanai S; Nagano T; Takano T; Shahzad MM; Ueland FR; Kelley JL; Roman LD
Surg Oncol; 2019 Jun; 29():25-32. PubMed ID: 31196490
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors for disease-free and overall survival of patients with uterine carcinosarcoma.
Şükür YE; Taşkın S; Varlı B; Ateş C; Güngör M; Ortaç F
Int J Clin Oncol; 2018 Feb; 23(1):114-120. PubMed ID: 28836024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
